ClinicalTrials.gg
Active, not recruitingNCT05882071Updated Oct 13, 2026

Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France

An observational study in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Active, not recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Boehringer Ingelheim · Observational

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
547,150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Planned enrollment
2nd of 34
547,150 · median 10,286
Started
2023
with 1 other
Observational
34 of 130
none open now
Registered
127th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 2nd largest by planned enrollment of the 34 observational ones that give a count, is one of 2 that started in 2023, is one of 34 observational ones, and was the 127th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objective of this study are:

- Describe the characteristics of all patients initiating sodium-glucose co-transporter-2 inhibitors (SGLT2i) and the modalities of prescriptions of these two drugs and the concomitant treatments.

The secondary objectives are:

  • Assess the occurrence of atheromatous cardiovascular events (unstable angina, fatal and non-fatal Myocardial infarction (MI), Transient ischemic attack (TIA), fatal and non-fatal stroke), deaths from all causes, hospitalization for heart failure and hospitalization for end-stage renal disease as main and related diagnoses during the exposure to the studied treatment
  • Assess the occurrence of the main safety events (ketoacidosis, lower limb amputation and Fournier's gangrene) during the exposure to the studied treatment
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients in France initiating a treatment with SGLT2i between April 1, 2020, and December 31, 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • population includes all patients initiating a treatment with SGLT2i between April 1, 2020, and December 31, 2024.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
547,150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients initiating treatment with SGLT2i

    Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)

  • Type 2 diabetes mellitus patients initiating SGLT2i

    Drug: Sodium/glucose cotransporter-2 inhibitors (SGLT2i)

Interventions

  • DrugSodium/glucose cotransporter-2 inhibitors (SGLT2i)

    Sodium/glucose cotransporter-2 inhibitors (SGLT2i)

06

What researchers measure

Primary outcomes

  1. Baseline characteristic: Age

    Time frame: up to 5 years

  2. Baseline characteristic: Gender

    Time frame: up to 5 years

  3. Baseline characteristic: Region of residence

    Time frame: up to 5 years

  4. Baseline characteristic: History of diabetes (date of first Long Term Disease (LTD) status related to diabetes)

    Time frame: up to 5 years

  5. Baseline characteristic: Type of diabetes

    Time frame: up to 5 years

  6. Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)

    Time frame: up to 5 years

Secondary outcomes

  1. Incidence rate of acute cardiovascular atheromatous events during the exposure period following initiation of the SGLT2i

    Time frame: up to 5 years

  2. Time from drug initiation to first event of acute cardiovascular atheromatous events

    Time frame: up to 5 years

  3. Incidence rate of heart failure hospitalization during the exposure period following initiation of the SGLT2i

    Time frame: up to 5 years

  4. Time from drug initiation to first event of heart failure hospitalization

    Time frame: up to 5 years

  5. Incidence rate of deaths all cause during the exposure period following initiation of the SGLT2i

    Time frame: up to 5 years

  6. Time from drug initiation to death all cause

    Time frame: up to 5 years

07

Study locations

1 site
  • Boehringer Ingelheim
    Paris, 75013, France
08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
May 31, 2023
StartActual
Nov 15, 2023
Primary completionEst.
Nov 30, 2026was Oct 2026
CompletionEst.
Nov 30, 2026was Oct 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 23, 2026→Nov 30, 2026
Oct 13, 2026
Study completion
Oct 23, 2026→Nov 30, 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Oct 23, 2026→Nov 30, 2026
    Study completion Oct 23, 2026→Nov 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05882071
Responsible party
Sponsor
First posted
May 31, 2023
Start date
Nov 15, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion